Genmab — Januar 2014
-
-
sorgløs... hmmm...
-
ja, på dage som disse her i 2014 glemmer man lidt at det ikke altid er sorgløst at være GEN'er
-
well - og så alligevel ikke. Det er sgu da lidt af en reversal GEN laver på en positiv dag. Forhåbentlig ikke dårlige nyheder på vej...
-
wouw - her er forklaringen - Pharmacyclics Inc. (PCYC: Quote) announced Tuesday morning that an Independent Data Monitoring Committee unanimously recommended that the Phase III RESONATE study, PCYC-1112-CA, a head-to-head comparison of IMBRUVICATM versus ofatumumab, be stopped early because the primary and a key secondary endpoint of the study have been met
-
primary endpoint var en sammenligning af pfs - http://clinicaltrials.gov/show/NCT01578707
-
det er i cll RR, de har lavet studiet. Kan ikke lige huske fps - men det er uden chlorambucil i den indikation
-
check evt. clinicaltrials - http://clinicaltrials.gov/show/NCT01578707
-
men vi har vist aldrig sat vores håb til noget med monoterapi alligevel...
-
faldet på GEN syntes voldsomt begrænset ifht stigningen på PCYC. Det er jo helt vildt! De får +1mia usd oven i kursen
-
Om ikke andet, så får vi testet vores teorier om den omkostningseffektive behandling
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind